The Annual CPDD meeting for 2025 will be held June 14-18, 2026 in New Orleans, LA.

In this session, Kathleen T. Brady, MD, PhD, of the Medical University of South Carolina, will discuss the NIDA N Clinical Trials Network (CTN) study CTN-0108, “Transcranial Magnetic Stimulation for the Treatment of Methamphetamine/Cocaine Use Disorder,” a pilot study that aims to determine the feasibility, effectiveness, and safety for 20 sessions of repetitive transcranial magnetic stimulation (rTMS) versus sham in adults with a diagnosed methamphetamine or cocaine use disorder. Dr. Brady, co-Principal Investigator for CTN-0108, will present the rationale for the study, including the literature supporting the use of rTMS in stimulant use disorder, as well as the study methodology and preliminary results. Objectives: List 3 key research findings supporting the use of TMS in treating substance use disorders Describe at least 3 key elements of the methodology for a trial of TMS in treating simulant use disorders Identify at least 3 preliminary data points from the CTN-0108 study CME and CE credits available! Sponsored by the Western States Node and the Northwest and Pacific Southwest ATTCs. About the presenter: Kathleen T. Brady, M.D., Ph.D. Distinguished University Professor Director, South Carolina Clinical and Translational Research Institute Medical University of South Carolina Dr. Brady is an experienced clinical and translational researcher and has been conducting scientific investigations and clinical work in the field of addictions and psychiatric disorders for over 40 years. Her focus is on pharmacotherapy and neurobiology of addictions, comorbid psychiatric disorders and gender differences in addictions.  She has received numerous federal research grants and has published over 400 peer-reviewed journal articles and edited/co-edited 10 books.  She is the former Vice President for Research at the Medical University of South Carolina.  She has been a member of AAAP for over 25 years  and has served at the President of the Association for Medical Education and Research in Substance Use Disorders (AMERSA), the American Academy of Addiction Psychiatry (AAAP) and is the immediate past president of International Society of Addiction Medicine (ISAM).  

The CTN Youth SIG is pleased to invite you to an upcoming presentation/webinar: Neural Substrates of Risk-Reduction Interventions for Adolescents Presenter: Uma Rao, MD (University of CA, Irvine; Children's Hospital of Orange County) Adolescence is characterized by increased experimentation, which is helpful in the progression towards autonomy but also increases vulnerability to psychopathology. A temporal disassociation in the maturation of “socio-emotional” (reward) and “cognitive-control” (self-regulation) neural systems creates a period of poor decision-making and heightened vulnerability to risk-taking (reward-seeking) behavior with the onset of puberty. This presentation describes whether neural circuitry changes governing adolescent decision-making can be used to improve intervention programs seeking to deter risky behaviors, especially among African Americans who are disproportionately impacted by their negative consequences. Register here!  Dr. Uma Rao is Professor of Psychiatry and Human Behavior at UC Irvine. Her research is focused on adolescent mood and substance use disorders, including neurobiological and psychosocial predictors of first onset and longitudinal clinical course of these disorders among at-risk youth (especially early-life adversity). In addition, she is involved in translational intervention research, examining biopsychosocial predictors of response to pharmacological and psychosocial interventions for these conditions.

CTN Primary Care SIG The Primary Care SIG aims to engage primary care in research, develop substance use treatment interventions relevant to community-based practice, and promote the transfer of evidence-based results from substance use research into community-based practices. Join the SIG for their next meeting: Loneliness and SUD in primary care Sebastian Tong, MD, MPH Associate Professor Department of Family Medicine University of Washington Register here!

Join the University of Cincinnati College of Medicine Center for Addiction Research, part of the CTN Ohio Valley Node, is hosting a Summer Speaker Series. The series will highlight cutting-edge UC addiction research and UC-community collaborations related to prevention and treatment. The final event in the series will be held on August 13, 2025, from 12-1pm ET: Psychedelics as Therapeutics for Substances Use Disorder: A Perspective on Their Neurobiology and Future Clinical Applications August 13, 2025, 12-1pm ET Host: T. John Winhusen, PhD, University of Cincinnati Presenters: Davide Amato, MSc, PhD, PD, University of Cincinnati Jon Kostas, Association for Prescription Psychedelics Register here!

This December, individuals on the frontlines of dissemination and implementation (D&I) science will convene to ensure that evidence is used to inform decisions that will improve the health of individuals and communities. Through a combination of plenaries, concurrent sessions, poster presentations, and workshops, the 18th Annual Conference on the Science of Dissemination and Implementation in Health, co-hosted by the National Institutes of Health (NIH) and AcademyHealth, supports the collective understanding of the research agenda, puts forth new findings, and identifies research priorities to set the field up for the next decade. 2025 Conference Theme Realizing the Benefits of Dissemination & Implementation Science This year’s conference theme will address our existing and future efforts to maximize the benefits of D&I science. While our field has identified and tested a range of strategies to ensure the adoption, integration, sustainment, and spread of effective health interventions, less attention has been focused on the ultimate benefits of successful dissemination and implementation studies. The 18th Annual Science of D&I Conference will explore success stories, methodological advancements, challenges, and opportunities to realize the benefits of our science across health care, community, and public health systems.